Drug developer and diagnostics specialist ValiRx (LON:VAL) hopes to achieve some "momentous milestones", it said, as it released final results.
Chief executive Dr Satu Vainikka said the firm will continue to progress its lead clinical development programmes and further advance the pre-clinical development pipeline, as well as increasing the company's commercial development activities.
"The company has made excellent progress over the past year and we will look to further establish ourselves at the forefront of personalised oncology development, hopefully achieving some momentous milestones".
Highlights of the year gone include encouraging findings following an early stage breast cancer study of VAL201.
In addition, GeneICE based lead compound VAL101 has shown good progress in the preclinical phase and the development programme is going ahead as planned, the firm said.
The company has also entered a distribution agreement with First Health Products for the distribution and sale of the firm's SELFCheck health screening products in the UK.
The loss after tax for the year to December 31 last year stood at £2.164 mln (2011: loss of £933,000) on revenues of £216,000 (2011: £455,000).